Sandra Sanchez - Pharma Mar Global Head
PHM Stock | EUR 73.50 0.40 0.55% |
Insider
Sandra Sanchez is Global Head of Pharma Mar SA
Phone | 34 91 846 60 00 |
Web | https://www.pharmamar.com |
Pharma Mar Management Efficiency
The company has return on total asset (ROA) of 0.1326 % which means that it generated a profit of $0.1326 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4705 %, meaning that it generated $0.4705 on every $100 dollars invested by stockholders. Pharma Mar's management efficiency ratios could be used to measure how well Pharma Mar manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | INSIDER Age | ||
Angel Naveiras | Melia Hotels | ||
Dario Clemente | Solaria Energa y | N/A | |
Carolina Martinoli | International Consolidated Airl | 53 | |
Nicholas FCA | International Consolidated Airl | 57 | |
Fernando Candela | International Consolidated Airl | N/A | |
Glenn Morgan | International Consolidated Airl | N/A | |
Vincent Hodder | International Consolidated Airl | 51 | |
Francisco Villaseor | Solaria Energa y | N/A | |
Pablo Garcia | Solaria Energa y | N/A | |
David Guengant | Solaria Energa y | N/A | |
Steven JD | Grifols SA | 63 | |
Andr Gerondeau | Melia Hotels | N/A | |
Sergio Pie | Cellnex Telecom SA | N/A | |
Maria Llano | Grifols SA | 58 | |
Jose Prieto | Cellnex Telecom SA | N/A | |
David Bell | Grifols SA | 69 | |
Chris Haynes | International Consolidated Airl | N/A | |
Yolanda Martinez | Cellnex Telecom SA | N/A | |
Juan Manjon | Solaria Energa y | N/A | |
Vctor Deu | Grifols SA | 46 | |
Montserrat Llamas | Grifols SA | 58 |
Management Performance
Return On Equity | 0.47 | |||
Return On Asset | 0.13 |
Pharma Mar SA Leadership Team
Elected by the shareholders, the Pharma Mar's board of directors comprises two types of representatives: Pharma Mar inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pharma. The board's role is to monitor Pharma Mar's management team and ensure that shareholders' interests are well served. Pharma Mar's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pharma Mar's outside directors are responsible for providing unbiased perspectives on the board's policies.
Pedro Puentes, Ex ViceChairman | ||
Jose SousaFaro, Ex Founder | ||
Sandra Sanchez, Global Head | ||
Elena Crespo, Director Admin | ||
Jos MartinezLosa, Director Relations | ||
Mara Caballero, Chief Officer | ||
Juan Nogues, Director Sales | ||
Juan Carretero, Founder | ||
Lara Vadillo, Communication Director | ||
Juan Pulido, Gen Directors |
Pharma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pharma Mar a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.47 | |||
Return On Asset | 0.13 | |||
Profit Margin | 0.35 % | |||
Operating Margin | 0.33 % | |||
Current Valuation | 1.07 B | |||
Shares Outstanding | 18.09 M | |||
Shares Owned By Insiders | 26.95 % | |||
Shares Owned By Institutions | 10.48 % | |||
Price To Earning | (38.29) X | |||
Price To Book | 5.69 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Pharma Stock
Pharma Mar financial ratios help investors to determine whether Pharma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharma with respect to the benefits of owning Pharma Mar security.